Home Pharmaceuticals Acute Sinusitis Market Size, Manufacturer, Share, Report to 2031

Acute Sinusitis Market

Acute Sinusitis Market Size, Share & Trends Analysis Report By Treatment (Diagnosis, Medication), By End-User (Hospitals & Clinics, ENTC Specialists, Research Institute, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH357DR
Study Period 2019-2031 CAGR 7.1%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 2.68 Billion
Forecast Year 2031 Forecast Year Market Size USD 4.96 Billion
Largest Market North America Fastest Growing Market Asia-Pacific
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The acute sinusitis market size was valued at USD 2.68 billion in 2022. It is projected to reach USD 4.96 billion by 2031, growing with a CAGR of 7.1% during the forecast period (2023–2031).

Acute sinusitis, also known as acute rhinosinusitis, is a medical condition in which the cavities around the nasal passage get swollen and inflamed. This infection impedes the drainage of the mucus to an extent where it builds around the sinuses. Cold-causing viral infection can cause acute sinusitis, and the symptoms include nasal congestion, sore throat, toothache, bad breath, and a reduced sense of smell and taste, among others. The symptoms of this infection should not be ignored as it can negatively impact the quality of life and worsen with time. In extreme cases, the sinus may need to be surgically removed, which will further increase medical visits and healthcare spending. Acute sinusitis is associated with few side effects, and serious complications are uncommon. The market is expanding due to the increasing prevalence of acute sinusitis, as well as the availability of numerous treatment and diagnostic alternatives. As acute sinusitis is becoming prevalent among the global population, manufacturers and the government are collaborating to develop better treatments. Investments in technical advancements by both the public and commercial sectors propel market growth. Lack of awareness about acute sinusitis is one of the biggest issues faced by developing countries, which might negatively impact the market growth in these nations. Moreover, the longer approval time for clinical trials and drugs by FDA is another challenge faced by pharmaceutical companies.

Market Dynamics

What are the factors driving the market growth?

Growing Prevalence of Acute Sinusitis

Acute sinusitis is the second most prevalent infectious condition diagnosed by general practitioners. Sinusitis occurs in 0.5% of all upper respiratory tract infections, with a frequency of 15–40 bouts per 1,000 patients per year, according to studies. Nearly 35 million people in the United States suffer from acute sinusitis, which is more prevalent in those aged 45 to 64. In the United States, almost 15 million patients annually seek medical attention for acute sinusitis. According to the World Allergy Organization, the annual prevalence of acute sinusitis ranges from 6 to 15% worldwide. Increasing incidences of acute sinusitis are anticipated to drive the global market over the forecast period.

Investment in R&D

Future expansion of the market is anticipated to be supported by a rising global trend in healthcare research and development expenditures. The emergence of biologics is one of the market's major trends in acute sinusitis. Currently, omalizumab is the ideal option. In the United States and Europe, this medication has been licensed for the treatment of severe allergic asthma. Scientists are evaluating the safety and efficacy of omalizumab for the treatment of chronic rhinosinusitis with nasal polyps. The successful introduction of biologics such as omalizumab is anticipated to boost the worldwide acute sinusitis market. Globally, key businesses are steadily increasing their investment in innovation and marketing as a result of an ongoing emphasis on cost management and improved process efficiency.

What are the factors restraining the market growth?

Lack of Awareness

There is a lack of awareness about acute sinusitis among the general population, particularly in developing countries, which may hinder the expansion of the market. In addition, a significant portion of the general population does not seek medical attention for acute sinusitis and waits for the condition to resolve itself. This is also owing to a lack of information regarding acute sinusitis' potential repercussions.

Regional Analysis

The global acute sinusitis market share regionally is segmented into North America, Europe, Asia-Pacific and Latin America, and the Middles East & Africa.

North America accounts for the largest share of the global market. The growth in North America is uplifted by its technical progression in diagnostic services, increased expenditure, and easy access to healthcare facilities. The increasing prevalence of chronic disease in the U.S. is boosting the market growth in the region. As per CDC, around 11% of Americans are affected with acute sinusitis. The prevalence of acute sinusitis is increasing at an alarming rate. To address this situation, the government and the manufacturers are working together to provide better treatment solutions and heavily investing in technological advancements. In addition, increasing preference for over-the-counter medications like decongestants, nasal sprays, and nasal corticosteroids are also anticipated to fuel the growth of the market in the years to come.

In Europe, a well-established healthcare infrastructure and system, the increasing prevalence of allergic rhinitis, and the easy availability of the products all contribute to the expansion of the market. The increasing prevalence of chronic sinusitis and the significant geographical disparities in sinus-related diseases in European countries are predicted to increase demand for its treatment. Similarly, the increasing incidence of allergic rhinitis is anticipated to have a comparable effect on the market. According to a study published in the World Allergy Organization Journal, Germany has a high prevalence of allergies, with over 20% of its population suffering from at least one allergy and only 10% deciding to treat it appropriately. The prevalence of chronic disorders such as asthma, rhinitis, and allergies has increased significantly in Europe. This increase is predicted to stimulate regional market growth. Due to Switzerland's increased emphasis on the healthcare and medical device industries, it is anticipated that the country will experience significant growth over the forecast period.

In the Asia Pacific, the prevalence of various acute and chronic diseases is increasing at an alarming rate. As per the Institute for Health Metrics and Evaluation, India holds 18% of the global population for chronic respiratory diseases. Moreover, rising demand for quality and cost-effective treatment is boosting the market growth in the region. Apart from this, the growing number of patients suffering from sinusitis and easy treatment availability in the region is driving market growth. Companies participating in the Asia Pacific regional market, such as Olympus Corp. and InnAccel Technologies, are concentrating on mergers and acquisitions in order to extend their product line and supply high-quality products at an accessible price to emerging markets.

Sinusitis is a highly prevalent condition that affects 5 million individuals annually in the Middle East and Africa. Due to advancements in diagnostic techniques and technical advancements, the of diagnosing acute sinusitis has increased. In addition, technological advancements enable various market participants to produce technically improved medical devices for treating sinusitis with less invasive techniques. In addition, foreign market participants like Medtronic plc, Smith & Nephew, and Olympus Corporation offer highly advanced devices. In addition, start-ups and local companies in developing nations of the LAMEA region are engaged in the development of innovative and affordable medical devices.

Report Scope

Report Metric Details
Segmentations
By Treatment
  1. Diagnosis
  2. Medication
By End-User
  1. Hospitals & Clinics
  2. ENTC Specialists
  3. Research Institute
  4. Others
Company Profiles Sanofi (France) Bristol-Myers Squibb (U.S.) Reddy’s Laboratory (India) Eli Lilly and Company (U.S.) Abbott (U.S.) Bayer AG(Germany) Novartis AG(Switzerland) AstraZeneca Plc. (U.K.) Merck & Co, Inc. (U.S.)
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global acute sinusitis market share is segmented by treatment, end-user, and region.

Based on treatment, the market is segmented into diagnosis and medication.

Diagnosis is further segmented into imaging tests, allergy tests, nasal endoscopy, and laboratory tests. Imaging is further divided into computed tomography and magnetic resonance imaging. Magnetic resonance imaging allows better differentiation of soft tissue structures within the sinuses as it uses strong magnetic fields and radio waves to produce internal images of the body. In addition, MRI is a non-invasive way to view inflammation, and other structures inside the body, which is further boosting segment growth.

Medication is sub-segmented into a saline nasal spray, nasal corticosteroids, decongestants, antibiotics, OTC pain relievers, and allergy shots, among others. The nasal corticosteroids segment is expected to hold a major market share as it is very effective at reducing inflammation. It is widely used to relieve symptoms such as sinus congestion, mucus production, and nasal swelling.

In terms of end-user, the market is segmented into hospitals & clinics, ENT specialists, and research institutes, among others.

The hospital segment is expected to hold the major market share for acute sinusitis following huge patient visits to the hospital for sinus treatment. The increasing frequency of acute sinusitis and favorable reimbursement criteria are expected to drive the expansion of the category. It is anticipated that the presence of technologically advanced infrastructure and medical equipment, as well as the capacity to undertake complex sinus procedures, will stimulate segment expansion.

It is anticipated that the number of academic institutions and research facilities working to improve health outcomes for diagnostic and therapeutic approaches will increase over the projected period. Clinical trials are being conducted in partnership between diagnostic and research firms.

Market Size By Treatment

Market Size By Treatment
  • Diagnosis
  • Medication
  • Recent Developments

    • February 2022- Olympus, a global leader in inventing and delivering breakthrough solutions for medical and surgical operations, announced that its CELERISTM single-use sinus debride system has received FDA certification and will soon be available on the market. The CELERIS system is designed for cutting, coagulation, debridement, and removal of thin bone and soft tissue in general ENT and sinus/rhinology treatments.
    • July 2021- GlaxoSmithKline (GSK) stated that the Food and Drug Administration (FDA) had authorized Nucala (mepolizumab) as a therapy for individuals with chronic rhinosinusitis with nasal polyps. This is a new indication for the monoclonal antibody mepolizumab, which targets interleukin-5 (IL-5).
    • August 2021- The European Commission (EC) authorized Xolair (omalizumab) as add-on therapy with intranasal corticosteroids (INC) for the treatment of people (18 years and older) with severe chronic rhinosinusitis with nasal polyps for whom therapy INC does not offer satisfactory disease control.

    Top Key Players

    Acute Sinusitis Market Share of Key Players

    Acute Sinusitis Market Share of Key Players
    Sanofi (France) Bristol-Myers Squibb (U.S.) Reddy’s Laboratory (India) Eli Lilly and Company (U.S.) Abbott (U.S.) Bayer AG(Germany) Novartis AG(Switzerland) AstraZeneca Plc. (U.K.) Merck & Co, Inc. (U.S.) Others

    Frequently Asked Questions (FAQs)

    What is the estimated growth rate (CAGR) of the global Acute Sinusitis market?
    The global Acute Sinusitis market size is growing at a CAGR of 7.1% from 2023 to 2031.
    North America has the largest share of the market.
    Growing prevalence of acute sinusitis is the key driver for the growth of the market.
    The key players in the global Market include Sanofi (France) ,Bristol-Myers Squibb (U.S.) ,Reddy’s Laboratory (India) ,Eli Lilly and Company (U.S.) ,Abbott (U.S.) ,Bayer AG(Germany) ,Novartis AG(Switzerland) ,AstraZeneca Plc. (U.K.) ,Merck & Co, Inc. (U.S.)


    We are featured on :